MedTrace Logo

A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors

NCT01631279 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2014-06-16

No results posted yet for this study

Summary

The purpose of this study is to determine the Maximum Tolerated Dose and the Dose-Limiting Toxicity of the drug to further evaluate safety and antitumor activity.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

PR610

Dose escalation of PR610 to determine maximum tolerated dose for weekly administration

Sponsors & Collaborators

  • Proacta, Incorporated

    lead INDUSTRY

Principal Investigators

  • Proacta Inc. · Proacta, Incorporated

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2015-03-31
Completion
2015-08-31

Countries

  • United States
  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01631279 on ClinicalTrials.gov